Molecular Chaperones in Parkinson's Disease – Present and Future

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Parkinson's Disease

• Publication date

  2011-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3233/JPD-2011-11044PMID 22279517PMCID PMC3264060
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Epidemiology of Parkinson's disease].

  2013cited by this paper
• Gene Therapy for Parkinson's Disease

  2012cited by this paper
• Hsc70 Protein Interaction with Soluble and Fibrillar α-Synuclein*

  2011cited by this paper
• Fighting neurodegeneration with rapamycin: mechanistic insights

  2011influential reference
• Protein homeostasis and aging: The importance of exquisite quality control.

  2011cited by this paper
• BAG3 and friends: Co-chaperones in selective autophagy during aging and disease

  2011cited by this paper
• Distinct Roles In Vivo for the Ubiquitin–Proteasome System and the Autophagy–Lysosomal Pathway in the Degradation of α-Synuclein

  2011cited by this paper
• Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies.

  2011cited by this paper
• Prospects of Statins in Parkinson Disease

  2011cited by this paper
• BAG3: a multifaceted protein that regulates major cell pathways

  2011cited by this paper
• Ubiquitinylation of α-Synuclein by Carboxyl Terminus Hsp70-Interacting Protein (CHIP) Is Regulated by Bcl-2-Associated Athanogene 5 (BAG5)

  2011cited by this paper
• α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation

  2011cited by this paper
• Heat‐shock protein 70 modulates toxic extracellular α‐synuclein oligomers and rescues trans‐synaptic toxicity

  2011cited by this paper
• Chemical modulators of autophagy as biological probes and potential therapeutics.

  2011influential reference
• Mitochondrial dysfunction induced by knockdown of mortalin is rescued by Parkin.

  2011cited by this paper
• 17-AAG increases autophagic removal of mutant androgen receptor in spinal and bulbar muscular atrophy.

  2011cited by this paper
• Molecular chaperones in protein folding and proteostasis

  2011cited by this paper
• In vivo demonstration that α-synuclein oligomers are toxic

  2011cited by this paper
• AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial.

  2011cited by this paper
• The accumulation of neurotoxic proteins, induced by proteasome inhibition, is reverted by trehalose, an enhancer of autophagy, in human neuroblastoma cells.

  2011cited by this paper
• Heat shock proteins

  2011cited by this paper
• Calcium dysregulation, mitochondrial pathology and protein aggregation in a culture model of amyotrophic lateral sclerosis: mechanistic relationship and differential sensitivity to intervention.

  2011influential reference
• Viral vector-mediated overexpression of α-synuclein as a progressive model of Parkinson's disease.

  2010cited by this paper
• The HSP70 Molecular Chaperone Is Not Beneficial in a Mouse Model of α-synucleinopathy

  2010influential reference
• The heat shock response: life on the verge of death.

  2010cited by this paper
• Genetic animal models of Parkinson's disease.

  2010cited by this paper
• 17-AAG Induces Cytoplasmic α-Synuclein Aggregate Clearance by Induction of Autophagy

  2010cited by this paper
• Celastrol: Molecular targets of Thunder God Vine.

  2010cited by this paper
• Are synucleinopathies prion-like disorders?

  2010cited by this paper
• Genetic mouse models of Parkinson's disease The state of the art.

  2010cited by this paper
• Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial.

  2010cited by this paper
• Cell-produced-synuclein oligomers are targeted to , and impair , the 26 S proteasome

  2010cited by this paper
• Gene Therapy in Parkinson’s Disease

  2010cited by this paper
• Molecular chaperone-mediated rescue of mitophagy by a Parkin RING1 domain mutant

  2010cited by this paper
• Gene therapy for Parkinson's disease

  2010cited by this paper
• Enhancement of Proteasome Activity by a Small-Molecule Inhibitor of Usp14

  2010influential reference
• Chaperone-mediated autophagy markers in Parkinson disease brains.

  2010cited by this paper
• Valproic Acid is Neuroprotective in the Rotenone Rat Model of Parkinson’s Disease: Involvement of α-Synuclein

  2010cited by this paper
• Trehalose ameliorates dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through autophagy activation.

  2010cited by this paper
• Mutant superoxide dismutase 1 overexpression in NSC-34 cells: effect of trehalose on aggregation, TDP-43 localization and levels of co-expressed glycoproteins.

  2010influential reference
• Brain-Permeable Small-Molecule Inhibitors of Hsp90 Prevent α-Synuclein Oligomer Formation and Rescue α-Synuclein-Induced Toxicity

  2010cited by this paper
• Heat shock protein 90 in neurodegenerative diseases

  2010cited by this paper
• Cell-penetrating peptide technology to deliver chaperones and associated factors in diseases and basic research.

  2010cited by this paper
• Reduction of β-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease

  2010cited by this paper
• Targeting the dynamic HSP90 complex in cancer

  2010cited by this paper
• Molecular chaperones as rational drug targets for Parkinson's disease therapeutics.

  2010cited by this paper
• Neurotoxic in vivo models of Parkinson's disease recent advances.

  2010cited by this paper
• Modulation of Heat Shock Transcription Factor 1 as a Therapeutic Target for Small Molecule Intervention in Neurodegenerative Disease

  2010cited by this paper
• Stable α-Synuclein Oligomers Strongly Inhibit Chaperone Activity of the Hsp70 System by Weak Interactions with J-domain Co-chaperones*

  2010cited by this paper
• Potent neuroprotective effects of novel structural derivatives of valproic acid: potential roles of HDAC inhibition and HSP70 induction.

  2010cited by this paper
• Parkinson's disease (vol 373, pg 2055, 2009)

  2009cited by this paper
• Activation of the heat shock response in a primary cellular model of motoneuron neurodegeneration-evidence for neuroprotective and neurotoxic effects

  2009cited by this paper
• Pre‐fibrillar α‐synuclein variants with impaired β‐structure increase neurotoxicity in Parkinson's disease models

  2009cited by this paper
• The Molecular Chaperone Hsp90 Modulates Intermediate Steps of Amyloid Assembly of the Parkinson-related Protein α-Synuclein*

  2009influential reference
• Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease.

  2009cited by this paper
• CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity

  2009cited by this paper
• Intracerebral transplantation of neural stem cells combined with trehalose ingestion alleviates pathology in a mouse model of Huntington's disease

  2009cited by this paper
• Delivery of HSF1(+) protein using HIV-1 TAT protein transduction domain

  2009cited by this paper
• Long‐term dietary administration of valproic acid does not affect, while retinoic acid decreases, the lifespan of G93A mice, a model for amyotrophic lateral sclerosis

  2009influential reference
• Update on Hsp90 inhibitors in clinical trial.

  2009cited by this paper
• The Shock of Aging: Molecular Chaperones and the Heat Shock Response in Longevity and Aging – A Mini-Review

  2009cited by this paper
• SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK.

  2009cited by this paper
• Induction of heat shock protein 70 reduces the alteration of striatal electrical activity caused by mitochondrial impairment.

  2009cited by this paper
• Genome-Wide Association Study reveals genetic risk underlying Parkinson’s disease

  2009cited by this paper
• 17-DMAG ameliorates polyglutamine-mediated motor neuron degeneration through well-preserved proteasome function in an SBMA model mouse.

  2009cited by this paper
• Valproic acid induces functional heat‐shock protein 70 via Class I histone deacetylase inhibition in cortical neurons: a potential role of Sp1 acetylation

  2009cited by this paper
• Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a Drosophila model of Parkinson's disease

  2009cited by this paper
• Chaperone proteostasis in Parkinson's disease: stabilization of the Hsp70/α‐synuclein complex by Hip

  2009cited by this paper
• Can we achieve neuroprotection with currently available anti-parkinsonian interventions?

  2009cited by this paper
• Rab11a and HSP90 Regulate Recycling of Extracellular α-Synuclein

  2009cited by this paper
• Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions.

  2009cited by this paper
• Regulation of LRRK2 Stability by the E3 Ubiquitin Ligase CHIP

  2009cited by this paper
• Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease.

  2008cited by this paper
• DJ-1 Modulates α-Synuclein Aggregation State in a Cellular Model of Oxidative Stress: Relevance for Parkinson's Disease and Involvement of HSP70

  2008cited by this paper
• Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis

  2008influential reference
• TAT‐Hsp40 inhibits oxidative stress‐mediated cytotoxicity via the inhibition of Hsp70 ubiquitination

  2008cited by this paper
• SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase–Dependent Cancers

  2008cited by this paper
• Interactions between Hsp70 and the hydrophobic core of alpha-synuclein inhibit fibril assembly.

  2008cited by this paper
• CHIP Targets Toxic α-Synuclein Oligomers for Degradation*

  2008cited by this paper
• Valproic acid inhibits Aβ production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models

  2008cited by this paper
• L347P PINK1 mutant that fails to bind to Hsp90/Cdc37 chaperones is rapidly degraded in a proteasome-dependent manner.

  2008cited by this paper
• Formation of Toxic Oligomeric α-Synuclein Species in Living Cells

  2008cited by this paper
• Heat Shock Transcription Factor 1-activating Compounds Suppress Polyglutamine-induced Neurodegeneration through Induction of Multiple Molecular Chaperones*

  2008influential reference
• Characterization of PINK1 processing, stability, and subcellular localization

  2008cited by this paper
• Aberrant Interaction between Parkinson Disease-associated Mutant UCH-L1 and the Lysosomal Receptor for Chaperone-mediated Autophagy*

  2008cited by this paper
• HSP70 and constitutively active HSF1 mediate protection against CDCrel-1-mediated toxicity.

  2008cited by this paper
• Targeting Hsp90: small-molecule inhibitors and their clinical development.

  2008cited by this paper
• Tat‐Hsp70 protects dopaminergic neurons in midbrain cultures and in the substantia nigra in models of Parkinson’s disease

  2008influential reference
• Why have we failed to achieve neuroprotection in Parkinson's disease?

  2008cited by this paper
• Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1G93A mouse model of ALS

  2008cited by this paper
• Effect of trehalose on protein structure

  2008cited by this paper
• Viral vectors for in vivo gene transfer in Parkinson's disease: properties and clinical grade production.

  2008cited by this paper
• Accumulation and clearance of α‐synuclein aggregates demonstrated by time‐lapse imaging

  2008cited by this paper
• Proteomic Identification of Novel Proteins in Cortical Lewy Bodies

  2007cited by this paper
• Different Species of α-Synuclein Oligomers Induce Calcium Influx and Seeding

  2007cited by this paper
• Identification of potential protein interactors of Lrrk2.

  2007cited by this paper
• Pharmacological induction of heat shock protein exerts neuroprotective effects in experimental intracerebral hemorrhage.

  2007cited by this paper
• Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility?

  2007cited by this paper
• Different species of alpha-synuclein oligomers induce calcium influx and seeding.

  2007cited by this paper
• Celastrol inhibits polyglutamine aggregation and toxicity though induction of the heat shock response

  2007cited by this paper

• Decoding the role of large heat shock proteins in the progression of neuroinflammation‐mediated neurodegenerative disorders

  2025cites this paper
• Ubiquitin Carboxyl-Terminal Hydrolase L1 and Its Role in Parkinson’s Disease

  2024cites this paper
• Content CN-21-5

  2023influential citation
• Molecular Chaperones as Therapeutic Target: Hallmark of Neurodegenerative Disorders

  2023cites this paper
• An ankyrin repeat chaperone targets toxic oligomers during amyloidogenesis

  2023cites this paper
• UBA52 Is Crucial in HSP90 Ubiquitylation and Neurodegenerative Signaling during Early Phase of Parkinson’s Disease

  2022influential citation
• The Innate and Adaptive Immune Cells in Alzheimer's and Parkinson's Diseases

  2022cites this paper
• Proteostasis in Parkinson's disease: Recent development and possible implication in diagnosis and therapeutics.

  2022cites this paper
• Intranasal HSP70 administration protects against dopaminergic denervation and modulates neuroinflammatory response in the 6-OHDA rat model

  2021cites this paper
• Genetic basis of susceptibility to low‐dose paraquat and variation between the sexes in Drosophila melanogaster

  2021cites this paper
• The penalty of stress ‐ Epichaperomes negatively reshaping the brain in neurodegenerative disorders

  2021cites this paper
• α-Synuclein: An All-Inclusive Trip Around its Structure, Influencing Factors and Applied Techniques

  2021cites this paper
• Intermediates of α-synuclein aggregation: Implications in Parkinson's disease pathogenesis.

  2021cites this paper
• Calmodulin and Its Binding Proteins in Parkinson’s Disease

  2021cites this paper
• Heat Shock Proteins, a Key Modulator of Neuroinflammation in Alzheimer’s Disease

  2020cites this paper
• Protein Degradation and the Pathologic Basis of Phenylketonuria and Hereditary Tyrosinemia

  2020cites this paper
• Clinical Features of Parkinson’s Disease: The Evolution of Critical Symptoms

  2020cites this paper
• Molecular Chaperones in Neurodegeneration

  2020cites this paper
• Expression of HSP70 Heat-Shock Proteins under Oxidative Stress

  2020cites this paper
• Chaperones and Proteostasis: Role in Parkinson’s Disease

  2020cites this paper
• LRRK2 and α-Synuclein: Distinct or Synergistic Players in Parkinson’s Disease?

  2020cites this paper
• U-133, a Chaperone Inducer, Eliminates Sleep Disturbances in a Model of the Preclinical Stage of Parkinson’s Disease in Aged Rats

  2020cites this paper
• Heat Shock Proteins in Neural Signaling: Implications in Health and Disease

  2019cites this paper
• Molecular chaperones biochemistry and role in neurodegenerative diseases.

  2019cites this paper
• Afobazole Restores the Dopamine Level in a 6-Hydroxydopamine Model of Parkinson’s Disease

  2019cites this paper
• Protein Misfolding Diseases and Therapeutic Approaches.

  2019cites this paper
• Overlap in synaptic neurological condition susceptibility pathways and the neural pannexin 1 interactome revealed by bioinformatics analyses

  2019cites this paper
• HSP90-incorporating chaperome networks as biosensor for disease-related pathways in patient-specific midbrain dopamine neurons

  2018cites this paper
• New HSF1 inducer as a therapeutic agent in a rodent model of Parkinson's disease

  2018cites this paper
• Regulación de la interacción de α-sinucleína con membranas lipídicas por el sistema Hsp70 humano

  2018cites this paper
• Neurodegenerative Diseases: Regenerative Mechanisms and Novel Therapeutic Approaches

  2018cites this paper
• The Continuum of Aging and Age-Related Diseases: Common Mechanisms but Different Rates

  2018cites this paper
• Factor inhibiting HIF1–A novel target of SUMOylation in the human placenta

  2017cites this paper
• Formation of neurodegenerative aggresome and death-inducing signaling complex in maternal diabetes-induced neural tube defects

  2017cites this paper
• Current understanding of the molecular mechanisms in Parkinson's disease: Targets for potential treatments

  2017influential citation
• α-Synuclein pathology and mitochondrial dysfunction: Studies in cell models for Parkinson’s disease

  2017cites this paper
• Expanding role of molecular chaperones in regulating α-synuclein misfolding; implications in Parkinson’s disease

  2017cites this paper
• The Neuroprotective Role of Protein Quality Control in Halting the Development of Alpha-Synuclein Pathology

  2017cites this paper
• NEUROPROTECTIVE ROLE OF BIMOCLOMOL IN ECTOPIC CELL CYCLE IN PARKINSON’S DISEASE: NEW INSIGHTS

  2017cites this paper
• Factors that Contribute to de novo Protein Misfolding and Prion Formation in Saccharomyces cerevisiae

  2017cites this paper
• Protein Quality Control by Molecular Chaperones in Neurodegeneration

  2017cites this paper
• Similarity and Differences in Inflammation-Related Characteristics of the Peripheral Immune System of Patients with Parkinson’s and Alzheimer’s Diseases

  2017cites this paper
• Targeting chaperones, heat shock factor-1, and unfolded protein response: Promising therapeutic approaches for neurodegenerative disorders.

  2017cites this paper
• A toxic imbalance of Hsp70s in Saccharomyces cerevisiae is caused by competition for cofactors

  2017cites this paper
• Impact of N-Acetyl-L-Cysteine on the Pathology of Experimental Parkinson’s Disease in Vivo

  2016cites this paper
• Identification of chaperones in a MPP+-induced and ATRA/TPA-differentiated SH-SY5Y cell PD model.

  2016cites this paper
• Investigational α-synuclein aggregation inhibitors: hope for Parkinson’s disease

  2016influential citation
• Slow-wave sleep and molecular chaperones

  2016cites this paper
• Changes in sleep characteristics of rat preclinical model of Parkinson’s disease based on attenuation of the ubiquitin—proteasome system activity in the brain

  2016cites this paper
• Structure of amyloid oligomers and their mechanisms of toxicities: Targeting amyloid oligomers using novel therapeutic approaches.

  2016cites this paper
• Functional Analysis of Cytosolic Hsp70 Nucleotide Exchange Factor Networks in Yeast

  2014cites this paper
• ASYN and tau interaction : new drug target for neurodegenerative diseases

  2014cites this paper
• Discovery of the neuroprotective effects of alvespimycin by computational prioritization of potential anti‐parkinson agents

  2014cites this paper
• The chaperone-like protein 14-3-3η interacts with human α-synuclein aggregation intermediates rerouting the amyloidogenic pathway and reducing α-synuclein cellular toxicity.

  2014cites this paper
• Exogenous protein HSP70 blocks neurodegeneration in the rat model of the clinical stage of Parkinson’s disease

  2014cites this paper
• iTRAQ-based quantitative proteomics study on the neuroprotective effects of extract of Acanthopanax senticosus harm on SH-SY5Y cells overexpressing A53T mutant α-synuclein.

  2014cites this paper
• Emerging role of autophagy in pediatric neurodegenerative and neurometabolic diseases

  2014cites this paper
• Affinity of dihydropyrimidone analogues for adenosine A1 and A2A receptors

  2014cites this paper
• Heat shock protein 90 is a potential therapeutic target for ameliorating skeletal muscle abnormalities in Parkinson's disease

  2014cites this paper
• Sesamol and naringenin reverse the effect of rotenone-induced PD rat model.

  2013cites this paper
• Molecular chaperones and protein folding as therapeutic targets in Parkinson’s disease and other synucleinopathies

  2013influential citation
• Advances in the genetics of Parkinson disease

  2013cites this paper
• Restoring impaired protein metabolism in Parkinson's disease — TFEB‐mediated autophagy as a novel therapeutic target

  2013cites this paper
• Smoking-related mortality in the United States.

  2013cites this paper
• Smoking-related mortality in the United States.

  2013cites this paper
• An investigation into the molecular aetiology of Parkinson's disease in South African patients

  2013cites this paper
• Unraveling the mechanisms of alpha-synuclein aggregation and toxicity

  2013cites this paper
• Investigational surgical therapies

  2013cites this paper
• Effect of mutations in DUNC-45 on its activity as a myosin chaperone, using Drosophila as a modelm

  2013cites this paper
• Proteotoxicity and cardiac dysfunction.

  2013cites this paper
• Les inclusions intracellulaires sont-elles toujours des témoins d'un trouble de la protéolyse intracellulaire ?

  2012cites this paper
• The role of α-synuclein in neurodegeneration — An update

  2012cites this paper
• Transcriptional Regulation of Alpha-synuclein by GATA2 in Substantia Nigra

  2012cites this paper
• Systematic comparison of the effects of α-synuclein mutations on aggregation in Parkinson’s Diseases

  2012cites this paper
• [New insights into intracellular inclusions and intracellular proteolysis].

  2012cites this paper
• Chaperonopathies and chaperonotherapy. Hsp60 as therapeutic target in cancer: potential benefits and risks.

  2012cites this paper
• Protein degradation pathways in Parkinson’s disease: curse or blessing

  2012cites this paper
• Molecular Chaperones and Co-Chaperones in Parkinson Disease

  2012cites this paper